Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Disease
Sponsor: Bayer
This PHASE1 trial investigates Chagas Disease and is currently completed. Bayer leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2019 — Jan 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .